Effect of rosuvastatin treatment on cholesterol efflux from human macrophages

Neuroendocrinology Letters

Volumn 32, Issue SUPPL. 2, 2011, Pages 24-28

  Kralova Lesna, Ivana ^a   Adamkova, Vera ^a   Pagacova, Libuse ^a  

^a INSTITUTE FOR CLINICAL AND EXPERIMENTAL MEDICINE   (Czech Republic)

Author keywords

Cholesterol efflux; Lipoproteins; Macrophages; Reverse cholesterol transport; Statins

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN B; CARBON 14; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; ROSUVASTATIN; TRIACYLGLYCEROL;

ADULT; ARTICLE; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL TRANSPORT; CLINICAL ARTICLE; DYSLIPIDEMIA; FEMALE; HUMAN; HUMAN CELL; LIPID METABOLISM; MACROPHAGE; MALE; MIXED DYSLIPIDEMIA; RADIOACTIVITY;

EID: 84857431420     PISSN: 0172780X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Argmann CA, Edwards JY, Sawyez CG, O'Neil CH, Hegele RA, Pickering JG, Huff MW (2005). Regulation of macrophage cholesterol efflux through hydroxymethylglutaryl-CoA reductase inhibition: a role for RhoA in ABCA1-mediated cholesterol efflux. J Biol Chem. 280: 22212-22221. (Pubitemid 40827878)
2. Berrougui H, Cloutier M, Isabelle M, Khalil A (2006). Phenolic-extract from argan oil (Argania spinosa L.) inhibits human low-density lipoprotein (LDL) oxidation and enhances cholesterol efflux from human THP-1 macrophages. Atherosclerosis. 184: 389-396. (Pubitemid 43049725)
3. Boden WE (2000). High-density lipoprotein cholesterol as an independent risk factor in cardiovascular disease: assessing the data from Framingham to the Veterans Affairs High - Density Lipoprotein Intervention Trial. Am J Cardiol. 86: 19L-22L.
4. Duffy D, Rader DJ (2009). Update on strategies to increase HDL quantity and function. Nat Rev Cardiol. 6: 455-463.
5. von Eckardstein A, Hersberger M, Rohrer L. (2005). Current understanding of the metabolism and biological actions of HDL. Curr Opin Clin Nutr Metab Care. 8: 147-152. (Pubitemid 40289474)
6. Jones PH, Hunninghake DB, Ferdinand KC, Stein EA, Gold A, Caplan RJ, et al (2004). Statin therapies for elevated lipid levels compared across doses to rosuvastatin study group. Effects of rosuvastatin versus atorvastatin, simvastatin, and pravastatin on non-high-density lipoprotein cholesterol, apolipoproteins, and lipid ratios in patients with hypercholesterolemia: additional results from the STELLAR trial. Clin Ther. 26: 1388-1399. (Pubitemid 39572153)
7. Králová Lesná I, Suchanek P, Kovar J, Poledne R (2008). Replacement of dietary saturated fatty acids by polyunsaturated fatty acids in diet and reverse cholesterol transport. J Lipid Res. 49: 2414-2418.
8. Králová Lesná I, Suchanek P, Stavek P, Poledne R. (2009). Life style change and reverse cholesterol transport in obese women. Physiol Res. 58 suppl. 1: S47-S52.
9. McGillicuddy FC, de la Llera Moya M, Hinkle CC, Joshi MR, Chiquoine EH, Billheimer JT et al. (2009). Inflammation impairs reverse cholesterol transport in vivo. Circulation. 119: 1135-1145.
10. Montoya MT, Porres A, Serrano S, Fruchart JC, Mata P, Gerique JA et al (2002). Fatty acid saturation of the diet and plasma lipid concentrations, lipoprotein particle concentrations, and cholesterol efflux capacity. Am J Clin Nutr. 75: 484-491. (Pubitemid 34174941)
11. Poledne R, Kralova Lesna I (2009). Přímé měření reverzního transportu cholesterolu. [Direct evaluation of reverse cholesterol transport (In Czech with English abstract). Klin Biochem Metabol. 17: 97-100.
12. Schneck DW, Knopp RH, Ballantyne CM, McPherson R, Chitra RR, Simonson SG (2003). Comparative effects of rosuvastatin and atorvastatin across their dose ranges in patients with hypercholesterolemia and without active arterial disease. Am J Cardiol. 91: 33-41. (Pubitemid 36054166)
13. Schuster H (2003). Rosuvastatin - a highly effective new 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor: review of clinical trial data at 10-40 mg doses in dyslipidemic patients. Cardiology. 99: 126-139.
14. Sviridov D, Hoang A, Ooi E, Watts G, Barrett PHR, Nestel P (2008). Indices of reverse cholesterol transport in subjects with metabolic syndrome after treatment with rosuvastatin. Atherosclerosis. 197: 732-739. (Pubitemid 351417870)
15. Quin S, Koga T, Ganji SH, Kamanna VS, Kashyap ML (2008). Rosuvastatin selectively stimulates apolipoprotein A-I but not apolipoprotein A-II synthesis in Hep G2 cells. Metabolism. 57: 973-979. (Pubitemid 351814690)
16. Tato F, Vega GL, Grundy SM (1997). Determinants of plasma HDL-cholesterol in hypertriglyceridemic patients. Role of cholesterolester transfer protein and lecithin cholesteryl acyl transferase. Arterioscler Thromb Vasc Biol. 17: 56-63. (Pubitemid 27057325)
17. Uehara Y, Miura S, von Eckardstein A, Abe S, Fujii A, Y Matsuo et al. (2007). Unsaturated fatty acids suppress the expression of the ATP-binding cassette transporter G1 (ABCG1) and ABCA1 genes via an LXR/RXR responsive element. Atherosclerosis. 191: 11-21. (Pubitemid 46227424)
18. de Vries R, Kerstens MN, Sluiter WJ, Groen AK, van Tol A, Dullaart RP (2005). Cellular cholesterol efflux to plasma from moderately hypercholesterolaemic type 1 diabetic patients is enhanced, and is unaffected by simvastatin treatment. Diabetologia. 48: 1105-1113. (Pubitemid 40909645)
19. Wong J, Quinn CM, Gelissen IC, Jessup W, Brown AJ (2008). The effect of statins on ABCA1 and ABCG1 expression in human macrophages is influenced by cellular cholesterol levels and extent of differentiation. Atherosclerosis. 196: 180-189.
20. Yamashita S, Tsubakio-Yamamoto K, Ohama T, Nakagawa-Toyama Y, Nishida M (2010). Molecular mechanisms of HDL-cholesterol elevation by statins and its effects on HDL functions. J Atheroscler Thromb. 17: 436-451.